Zusammenfassung
Im Arzneiverordnungs-Report ist seit 1986 auf pharmakologisch-the-rapeutisch begründete Einsparpotentiale in der Arzneitherapie hingewiesen worden. Im Vordergrund standen zunächst die Rationalisierungspotentiale durch konsequente Anwendung von Generika und der relativ große Verordnungsanteil von Arzneimitteln mit umstrittener therapeutischer Wirksamkeit. Vor zwei Jahren wurden im Arzneiverordnungs-Report 1999 erstmals weitere Einsparpotentiale für Wirkstoffe mit pharmakologisch gleichwertigen Eigenschaften (Analogpräparate) berechnet.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Agence Francaise de Securite Sanitaire des Produits de Sante (2001): Reevaluation du service medical rendu de 4500 specialites pharmaceutiques. 07.06.2001.http://www.agmed.sante.gouv.fr
Bazell R.J: (1971): Drug efficacy study: FDA yields on fixed combinations. Science 172: 1013–1015.
Birks J.S., Melzer D. (2000): Donepezil for mild and moderate Alzheimer’s disease.Cochrane Database Syst. Rev. 2: CD001190.
Dimenas E., Ostergren J., Lindvall K., Dahlof C., Westergren G., de Faire U. (1990):Comparison of CNS-related subjective symptoms in hypertensive patients terated with either a new controlled release (CR/ZOK) formulation of metoprolol or atenolol. J. Clin. Pharmacol. 30 (2 Suppl.): S82–90.
Garattini L., Tediosi F. (2000): A comparative analysis of generics markets in five European countries. Health Policy 51:149–162.
Griffin J.P. (1996): A historical survey of UK government measures to control the NHS medicines expenditure from 1948 to 1996. Pharmacoeconomics 10: 210–224.
Gysling E., Kochen M. (1987): Beschränkung als Prinzip rationaler Pharmakotherapie. Pharma-Kritik 9:1–4.
Honig E.G., Ingram R.H.Jr. (2001): Chronic bronchitis, emphysema, and airways obstruction. In: Braunwald E., Hauser S.L., Fauci A.S., Longo D.L., Kasper D.L., Jameson L.J. (eds.): Harrison’s Principles of Internal Medicine. 15th ed., McGraw Hill, New York, San Francisco,Washington, pp. 1491–1499.
Kassenärztliche Bundesvereinigung (2000): Aktionsprogramm 2000. Rationale Arzneimitteltherapie unter Bedingungen der Rationierung, Köln.
Kessler D.A., Rose J.L., Temple R.J., Schapiro R., Griffin J.P. (1994): Therapeutic-class wars - drug promotion in a competitive marketplace. N. Engl. J. Med. 331: 1350–1353.
Mattison N. (1986): Pharmaceutical innovation and generic drug competition in the USA: effect of the drug price competition and patent term restoration act of 1984. Pharm. Med. 1: 177–185.
Mohs R., Doody R., Morris J., Ieni J.R., Rogers S.L., Perdomo C.A., Pratt R.D. (1999): Donepezil preserves functional status in Alzheimer’s disease patients: results from a 1-year prospective placebo-controlled study. Eur. Neuropsychopharmacol. 9 (Suppl. 5): S328.
Noe L.L., Vreeland M.G., Pezzella S.M., Trotter J.P. (1999): A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure. Clin. Ther. 21: 854–866.
Nordic Council on Medicines (1985): Nordic drug index with DDD. NLN Publication No. 15, Uppsala.
Pavort I., Knox H. (1993): Pharmacokinetic optimization of inhaled steroid therapy in asthma. Clin. Pharmacokinet. 25:126–135.
Poole P.J., Black P.N. (2001): Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Brit. Med. J. 322:1271.
Snow V., Lascher S., Mottur-Pilson C., for the American College of Physicians American Society of Internal Medicine (2000): Clinical guideline I. Pharmacological treatment of acute major depression and dysthemia. Ann. Int. Med. 132: 739–742.
Staessen J.A., Fagard R., Thijs L., Celis H., Arabidze G.G. et al. (1997): Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 350: 757–764.
The CONSENSUS Trial Study Group (1987): Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316: 1429–1435.
The SOLVD Investigators (1991): Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325: 293–302.
Todd P.A., Goa K.L. (1992): Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 43: 346–381.
Tuomilehto J., Rastenyte D., Birkenhäger W.H., Thijs L., Antikainen R. et al. (1999): Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. N. Engl. J. Med. 340: 677–684.
UK Prospective Diabetes Study (UKPDS) Group (1998): Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–853.
Vargo D.L., Kramer W.G., Black P.K., Smith W.B., Serpas T., Brater D.C. (1995): Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide inpatients with congestive heart failure. Clin. Pharmacol. Ther. 57:601–609.
Winblad B., Engedal K., Soininen H., Verhey F., Waldemar G., Wimo A. et al. (1999): Donepezil enhances global function, cognition and activities of daily living compared with placebo in a one-year, double-blind trial in patients with mild to moderate Alzheimer’s disease. Ninth Congress of the International Psychogeriatric Association, August 15-20,1999, Vancouver, Canada.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwabe, U. (2001). Einsparpotentiale. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2001. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56434-5_50
Download citation
DOI: https://doi.org/10.1007/978-3-642-56434-5_50
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-42079-8
Online ISBN: 978-3-642-56434-5
eBook Packages: Springer Book Archive